Researchers at the University of Technology Sydney have created experimental compounds that prompt mitochondria to burn more calories safely. These mild mitochondrial uncouplers could offer a new approach to treating obesity without the deadly risks of past chemicals. The findings, published in Chemical Science, highlight potential benefits for metabolic health and aging.
A team led by Associate Professor Tristan Rawling at the University of Technology Sydney (UTS) has pioneered experimental compounds designed to make cells burn additional calories by altering mitochondrial function. Mitochondria, known as the cell's powerhouses, convert food into adenosine triphosphate (ATP), the body's chemical energy. The new molecules, called mild mitochondrial uncouplers, disrupt this process mildly, causing cells to consume more fats and release excess energy as heat rather than usable power.
Rawling explains the mechanism: "Mitochondrial uncouplers disrupt this process, triggering cells to consume more fats to meet their energy needs." He likens it to a hydroelectric dam, where uncouplers create a small leak, allowing energy to escape as heat instead of generating electricity.
This innovation builds on a fraught history. About a century ago, during World War I, French munitions workers exposed to 2,4-Dinitrophenol (DNP) experienced rapid weight loss, elevated temperatures, and fatalities. In the 1930s, DNP was marketed as a weight-loss drug for its effectiveness but was banned due to its toxicity—the therapeutic dose being perilously close to the lethal one.
The UTS study, in collaboration with Memorial University of Newfoundland, modified chemical structures to produce safer uncouplers. Some variants increased mitochondrial activity without harming cells or ATP production, unlike more aggressive predecessors. These mild versions also reduce oxidative stress, potentially aiding healthier metabolism, slowing aging processes, and protecting against conditions like dementia.
Obesity, a global issue linked to diabetes and cancer, often requires injectable medications with side effects. This research, published in 2026 in Chemical Science (DOI: 10.1039/D5SC06530E), offers a roadmap for safer oral treatments that could enhance calorie burn while supporting broader health benefits. Though early-stage, it addresses a critical need in public health.
